DR5 Antibody

• 产品编号：CST-3696S      品牌：CST       原厂货号：3696S
• 产品分类：抗体 > 一抗 > 蛋白特异性一抗
• 应用分类：

描述：

DR5 Antibody能够检测DR5蛋白的前体和成熟的形式的亚型1和2。未检测到与其它家族成员的交叉反应。该多克隆抗体是由合成的人源DR5亚型1蛋白半胱氨酸(248位)处肽段免疫动物而制备的。抗体由protein A和肽亲和层析技术纯化。

肿瘤坏死因子受体家族，包括TNF-RI、FAS、DR3、DR4、DR5和DR6，在各个生理系统细胞凋亡的调控中起着重要的作用（1,2）。受体被一个家族的细胞因子，包括TNF、FasL和TRAIL激活。它们的特点是含有一个高度保守、富含半胱氨酸的重复序列的胞外区和一个胞内保守的约80个氨基酸的死亡结构域（DD）。DD对于死亡信号转导的传递很重要，它通过招募其他的DD配体蛋白（FADD，TRADD，RIP）到死亡诱导信号复合物（DISC）来发挥作用，进而激活半胱天冬酶蛋白。DR5是肿瘤坏死因子相关的凋亡诱导配体（TRAIL）的一个受体，已证明能在多种类型的细胞中诱导细胞凋亡，并已被用于癌症治疗（1-5）。在结构上，DR5含有一个氨基末端的主要切割位点，随后是一个富含两个半胱氨酸重复序列的胞外区，然后是一个中央的跨膜结构域和羧基端的死亡结构域。DR5在多种组织广泛表达，是p53基因的转录靶点（6-8）。它通过一个FADD依赖途径诱导细胞凋亡。敲除DR5会导致对TRAIL介导的细胞凋亡的阻碍，以及一个对DNA损伤刺激的终止响应（9）。

1. Nagata, S. (1997) Cell 88, 355-365.
2. Thorburn, A. (2004) Cell. Signal. 16, 139-144.
3. Wiley, S.R. et al. (1995) Immunity 3, 673-82.
4. Walczak, H. et al. (1997) EMBO J. 16, 5386-97.
5. Chaudhary, P.M. et al. (1997) Immunity 7, 821-30.
6. MacFarlane, M. et al. (1997) J. Biol. Chem. 272, 25417-20.
7. Wu, G.S. et al. (2000) Adv. Exp. Med. Biol. 465, 143-51.
8. Wu, G.S. et al. (1997) Nat. Genet. 17, 141-3.
9. Finnberg, N. et al. (2005) Mol. Cell Biol. 25, 2000-13.

原厂资料：

Specificity / Sensitivity

DR5 Antibody detects the precursor and mature forms of isoforms 1 and 2 of DR5. Cross reactivity was not detected with other family members.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding cysteine 248 of isoform 1 of human DR5. Antibodies were purified by protein A and peptide affinity chromatography.

Background

The tumor necrosis factor receptor family, which includes TNF-RI, Fas, DR3, DR4, DR5, and DR6, plays an important role in the regulation of apoptosis in various physiological systems (1,2). The receptors are activated by a family of cytokines that include TNF, FasL, and TRAIL. They are characterized by a highly conserved extracellular region containing cysteine-rich repeats and a conserved intracellular region of about 80 amino acids termed the death domain (DD). The DD is important for transducing the death signal by recruiting other DD containing adaptor proteins (FADD, TRADD, RIP) to the death-inducing signaling complex (DISC), resulting in activation of caspases.

DR5 is a receptor for TNF-related apoptosis inducing ligand (TRAIL), which has been been shown to induce apoptosis in variety of cell types and has been targeted for cancer therapy (1-5). Structurally, DR5 contains an amino-terminal leader cleavage site followed by an extracellular region containing two cysteine-rich repeats, then a central transmembrane domain and a carboxy-terminal death domain. DR5 is expressed in a wide variety of tissues and is transcriptional target for p53 (6-8). It induces apoptosis through a FADD-dependent pathway. Deletion of DR5 leads to resistance in TRAIL-mediated apoptosis as well as an abrogated response to DNA-damaging stimuli (9).

1. Nagata, S. (1997) Cell 88, 355-365.
2. Thorburn, A. (2004) Cell. Signal. 16, 139-144.
3. Wiley, S.R. et al. (1995) Immunity 3, 673-82.
4. Walczak, H. et al. (1997) EMBO J. 16, 5386-97.
5. Chaudhary, P.M. et al. (1997) Immunity 7, 821-30.
6. MacFarlane, M. et al. (1997) J. Biol. Chem. 272, 25417-20.
7. Wu, G.S. et al. (2000) Adv. Exp. Med. Biol. 465, 143-51.
8. Wu, G.S. et al. (1997) Nat. Genet. 17, 141-3.
9. Finnberg, N. et al. (2005) Mol. Cell Biol. 25, 2000-13.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.